https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19335
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19335
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADSofosbuvir / Velpatasvir / Voxilaprevir can inhibit OATP1B1 and increase the plasma concentration of Pravastatin.
–
–
–
Possible increase of adverse effects.
Increased risk of myopathy and rhabdomyolysis.
Use this combination with caution.
No more than 40 mg per day is recommended.
Monitor for adverse effects.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
CK
Lipidic profile
| Reference number |
|---|
| # patients |
| HCV |
| Dose |
| Frequency |
| AUC |
| Cmax |
| 3379 |
|---|
| 19 |
| - |
| 400/100/200 mg |
| QD |
| 3379 |
|---|
| 19 |
| - |
| 40 mg |
| x 1 |
| + 116% (2.1x) |
| + 89% (1.9x) |
–